|Title||SARS-CoV-2 coinfection with additional respiratory virus does not predict severe disease: a retrospective cohort study.|
|Publication Type||Journal Article|
|Year of Publication||2021|
|Authors||Chekuri S, Szymczak WA, D Goldstein Y, Nori P, Rolon RMarrero, Spund B, Singh-Tan S, Mohrmann L, Assa A, Southern WN, Baron SW|
|Journal||J Antimicrob Chemother|
|Date Published||2021 Sep 23|
|Keywords||Coinfection, COVID-19, Humans, Pandemics, Retrospective Studies, SARS-CoV-2|
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) claimed over 4 million lives by July 2021 and continues to pose a serious public health threat.
OBJECTIVES: Our retrospective study utilized respiratory pathogen panel (RPP) results in patients with SARS-CoV-2 to determine if coinfection (i.e. SARS-CoV-2 positivity with an additional respiratory virus) was associated with more severe presentation and outcomes.
METHODS: All patients with negative influenza/respiratory syncytial virus testing who underwent RPP testing within 7 days of a positive SARS-CoV-2 test at a large, academic medical centre in New York were examined. Patients positive for SARS-CoV-2 with a negative RPP were compared with patients positive for SARS-CoV-2 and positive for a virus by RPP in terms of biomarkers, oxygen requirements and severe COVID-19 outcome, as defined by mechanical ventilation or death within 30 days.
RESULTS: Of the 306 SARS-CoV-2-positive patients with RPP testing, 14 (4.6%) were positive for a non-influenza virus (coinfected). Compared with the coinfected group, patients positive for SARS-CoV-2 with a negative RPP had higher inflammatory markers and were significantly more likely to be admitted (P = 0.01). Severe COVID-19 outcome occurred in 111 (36.3%) patients in the SARS-CoV-2-only group and 3 (21.4%) patients in the coinfected group (P = 0.24).
CONCLUSIONS: Patients infected with SARS-CoV-2 along with a non-influenza respiratory virus had less severe disease on presentation and were more likely to be admitted-but did not have more severe outcomes-than those infected with SARS-CoV-2 alone.
|Alternate Journal||J Antimicrob Chemother|
|PubMed Central ID||PMC8460099|
Rebecca Marrero Rolon, M.D.